3 Reasons to Buy Zoetis, and 1 Reason to Sell
Whether you're a doting dog mom or a steely-eyed cattle rancher, you'll probably agree that animals need healthcare, just as we do. Enter Zoetis (NYSE: ZTS), a multinational pharmaceutical player that caters exclusively to developing medicines and other healthcare goods for pets and livestock.
Thanks to its long history of developing and selling everything from pet pain pills to diagnostic hardware for veterinary clinics, this company has a lot to offer for investors of all stripes. To explore whether it's a smart choice for your portfolio, take a look at these three points in favor of buying Zoetis; then let's learn one reason you might do better to sell it.
The most compelling reason to buy Zoetis stock is that it's positioned to continue its long-term trend of penetrating its markets faster than the competition. It's already the largest competitor in the global markets for animal healthcare products intended for administration to companion animals, fish, swine, and cattle. In total, its addressable market within the animal health industry is estimated by management to be around $45 billion. And that market grew by around 5.8% each year, on average, over the last 20 years.
Source Fool.com
